Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 12Burkitt Lymphoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Smoldering Multiple Myeloma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Leukemia 2Down Syndrome 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Recurrence 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Lung Neoplasms 1Leukemia, Plasma Cell 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Anus Neoplasms 1

Interventions

dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Lenalidomide 2Dexamethasone 2Calcium Dobesilate 2iberdomide 1daratumumab 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Calcium Dobesilate × 30 days × Clear all
NCT04776395 2026-06-01

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Emory University

Phase 2 Recruiting
68 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡